Clinical Presentation & Protocol
Patient Usually Complains Of
Patient presents for follow-up of hepatic adenoma, beta-catenin activated subtype. History significant for [OCP use/anabolic steroid use/metabolic syndrome]. Patient reports [asymptomatic/RUQ discomfort/acute pain suggesting hemorrhage]. No history of cirrhosis or chronic viral hepatitis. Imaging confirms lesion characteristics consistent with beta-catenin activation (high risk of malignant transformation).
Clinical Examination Findings
Abdominal examination: Soft, non-distended. Palpable mass noted in [RUQ/epigastrium] if large. No evidence of hepatomegaly or stigmata of chronic liver disease (no jaundice, spider angiomata, or ascites). Hemodynamically stable; no signs of acute hemoperitoneum.
Treatment Protocol
Due to the beta-catenin activated subtype and associated high risk of malignant transformation (HCC), surgical resection is recommended regardless of lesion size. Discontinue all hormonal therapies (OCPs/androgens). Monitor liver function tests (LFTs) and serial cross-sectional imaging (MRI with Eovist) pending surgical intervention.